EUVIMEDEUVIMED entdecken
Crossref

Tradipitant (Nereus) for Motion Sickness

The Medical Letter on Drugs and Therapeutics · 22.06.2026 · 68 (1757) · 97-98

DOI: 10.58347/tml.2026.1757a ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 22.06.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved the oral substance P/neurokinin-1 (NK-1) receptor antagonist tradipitant (Nereus – Vanda) for prevention of vomiting induced by motion in adults. Tradipitant is the first drug to be approved for motion sickness in more than 40 years. Other oral substance P/NK-1 receptor antagonists (i.e., aprepitant, rolapitant, and netupitant) have been available for years for prevention of chemotherapy-induced nausea and vomiting.

Schlagwörter

Stichwörter der Autor:innen

BonineDramamineNereusTransderm Scopadverse effectsantihistaminesaprepitantdimenhydrinatedosagedrug interactionsefficacylactationmeclizinenetupitantpregnancy

Zitieren

APA

(2026). Tradipitant (Nereus) for Motion Sickness. The Medical Letter on Drugs and Therapeutics, 68(1757), 97-98. https://doi.org/10.58347/tml.2026.1757a

Vancouver

Tradipitant (Nereus) for Motion Sickness. The Medical Letter on Drugs and Therapeutics. 2026;68(1757):97-98. doi:10.58347/tml.2026.1757a

BibTeX
@article{euvimed2026,
  title = {Tradipitant (Nereus) for Motion Sickness},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1757},
  pages = {97--98},
  doi = {10.58347/tml.2026.1757a}
}
Kostenlos starten →